Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
The MDR certification reafirms that these products meet the highest safety, quality, and regulatory standards
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Subscribe To Our Newsletter & Stay Updated
